Medifast, Inc. has reported a notable decline in revenue for the third quarter of 2026, highlighting challenges within the company and the broader industry. The earnings report, filed on October 26, 2026, reveals a significant decrease in active earning coaches, which has directly impacted the company’s financial performance.
Medifast, known for its focus on metabolic health and wellness, operates under the SIC classification of Miscellaneous Food Preparations & Kindred Products. The company trades on the New York Stock Exchange under the ticker symbol MED. Recent filings include a Form 8-K on October 26, 2026, detailing the company’s financial results, alongside other filings related to insider transactions and share offerings.
The filing indicates that for the third quarter ended September 30, 2026, Medifast generated revenue of $72 million, a decline of 19.4% from $89.4 million in the same quarter of the previous year. This revenue drop is attributed primarily to a decrease in the number of active earning coaches, which fell by 47.7% to 10,200 compared to 19,500 in the prior year. The company also reported a net loss of $17.5 million, with a loss per diluted share of $1.57.
Nick Johnson, Medifast's CEO, noted in the earnings release, “The third quarter was about execution. With Trilivy now live, Reset Fuelings in our coaches’ hands, and our new compensation plan and Coach Hub launched, the major pieces of our 3.0 strategy are now in market.” He expressed optimism about the company’s trajectory, stating that coach productivity has improved year-over-year for the fourth consecutive quarter, which historically precedes coach growth and revenue growth.
Despite the challenges, the company reported an increase in average revenue per active earning coach, which rose to $7,064 from $4,585 in the previous year. This increase reflects a focus on creating a more efficient and productive coach network structure.
Medifast's restructuring efforts, part of a cost-saving initiative known as “Catalyst,” aim to streamline operations and reduce costs. The company is actively reassessing its distribution network and internal software usage to align resources with current revenue levels.
Looking ahead, Medifast anticipates that the number of active earning coaches may continue to decline through the end of 2026, influenced by the competitive landscape, particularly the rapid adoption of GLP-1 medications for weight loss. The company remains committed to enhancing its metabolic health offerings and believes it is on track to achieve profitability in the fourth quarter of 2026.
The filing does not specify what steps the company will take next, but with ongoing adjustments and a focus on improving coach engagement, Medifast aims to stabilize its operations and enhance its market position.